Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00265681
Other study ID # 03-119
Secondary ID RC -2004-0010
Status Completed
Phase N/A
First received
Last updated
Start date November 2004
Est. completion date December 2006

Study information

Verified date April 2007
Source HealthPartners Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective is to evaluate the effectiveness of telephone-based counseling in promoting smokeless tobacco cessation among residents of Minnesota. It is hypothesized that a greater proportion of individuals assigned to the proactive telephone calls will quit their use of smokeless tobacco products and all tobacco products compared to the comparison group not receiving those calls.


Description:

Smokeless Tobacco (ST) users have not been the focus of tobacco control campaigns in Minnesota. However, there are a significant number of adults in Minnesota who regularly use ST. There is a need for a low-cost cessation program that can be widely delivered to ST users who may have little or no access to conventional and/or group treatments. Self-help interventions can make a significant contribution in reaching this population. The telephone provides a unique low-cost delivery system that can expand the reach of a self-help cessation program to underserved groups of tobacco users. The primary objective is to evaluate the effectiveness of telephone-based counseling in promoting smokeless tobacco cessation among Minnesota residents. It is hypothesized that a greater proportion of individuals assigned to the telephone calling group will quit their use of smokeless tobacco products and all tobacco products compared to the comparison group not receiving calls. We plan to recruit 400 smokeless tobacco users who are interested in quitting their use of smokeless tobacco and randomize them to telephone counseling for smokeless tobacco cessation or to a comparison group that receives the same mailed self-help materials. All subjects will be assessed pre-intervention, and at 3- and 6-months.


Recruitment information / eligibility

Status Completed
Enrollment 400
Est. completion date December 2006
Est. primary completion date December 2006
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Age 18 or older. Use snuff or chewing tobacco weekly. Snuff or chewing tobacco are primary tobacco use. Exclusion Criteria: No access to a telephone. Primary tobacco use is cigarettes, cigar or pipe tobacco.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Phone counseling and written materials


Locations

Country Name City State
United States HealthPartners Research Foundation Bloomington Minnesota

Sponsors (2)

Lead Sponsor Collaborator
HealthPartners Institute Minnesota Partnership for Action Against Tobacco

Country where clinical trial is conducted

United States, 

References & Publications (1)

Boyle RG, Pronk NP, Enstad CJ. A randomized trial of telephone counseling with adult moist snuff users. Am J Health Behav. 2004 Jul-Aug;28(4):347-51. doi: 10.5993/ajhb.28.4.6. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Point prevalent abstinence from all tobacco after 3 months. Point prevalent abstinence from all tobacco after 3 months.
Primary Prolonged abstinence from all tobacco after 3 months. Prolonged abstinence from all tobacco after 3 months
Primary Number of subjects who abstained for at least 24 hours. Number of subjects who abstained for at least 24 hours.
Secondary Assess the relative costs of delivering the 2 interventions. Assess the relative costs of delivering the 2 interventions.
Secondary Use baseline data to predict successful tobacco cessation. Use baseline data to predict successful tobacco cessation.
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06021652 - Feasibility, Adoption and Efficacy of A Virtual Reality Smoking Cessation Program for Patients Undergoing Lung Cancer Screening N/A
Completed NCT02735382 - EHR-Based and Fax-Based Referral to a Tobacco Quitline: A Comparative Study N/A
Completed NCT02557919 - Families Reduce Exposure to Smoke at Home N/A
Completed NCT01570595 - Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV Phase 1/Phase 2
Completed NCT00786149 - Improving Varenicline Adherence and Outcomes in Homeless Smokers Phase 3
Completed NCT00387946 - Efficacy and Safety of Dianicline Treatment as an Aid to Smoking Cessation in Cigarette Smokers (AMERIDIAN) Phase 3
Completed NCT00218452 - Smoking Cessation for Young Adults Who Binge Drink - 1 Phase 0
Completed NCT00124683 - Treating Nicotine Dependence in Schizophrenic Individuals: Effectiveness of Bupropion - 1 Phase 2
Recruiting NCT04610931 - Study of the Effectiveness of a Virtual Reality Treatment in the Management of Smoking Cessation N/A
Enrolling by invitation NCT06042361 - Enhancing Equity in Smoke-free Housing N/A
Recruiting NCT04994444 - Preloading With Nicotine Replacement Therapy in HIV-positive Smokers to Improve Self-Efficacy and Quit Attempts Phase 2/Phase 3
Recruiting NCT04827420 - Mi QUIT CARE (Mile Square QUIT Community-Access-Referral-Expansion) N/A
Completed NCT05560243 - Tobacco Cessation Tailored to Patients Living With HIV (PLWH) in Brazil N/A
Completed NCT02721082 - Changing the Default for Tobacco Treatment Phase 4
Completed NCT01885221 - A Multi-Media Approach to Partner Support in Smokeless Tobacco Cessation (UCare-ChewFree) N/A
Completed NCT03445507 - Effectiveness of a Chat Bot for Smoking Cessation: a Pragmatic Trial in Primary Care. N/A
Completed NCT04540081 - Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and LivER Cancer N/A
Completed NCT03714191 - Optimizing the Tobacco Cessation Clinical Decision Support Tool.
Completed NCT03553992 - An Extended Facebook Intervention for Young Sexual and Gender Minority Smokers N/A
Completed NCT01699828 - Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET Phase 1/Phase 2